about
ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndromeAnalysis of the role of Igf2 in adrenal tumour development in transgenic mouse modelsPancreatic ductal and acinar cell neoplasms in Carney complex: a possible new associationAldo keto reductase 1B7 and prostaglandin F2alpha are regulators of adrenal endocrine functions.ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional ConsequencesCushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout miceMacronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumorsPrimary Aldosteronism and ARMC5 Variants.Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma.Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumorsComparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cellsNovel Grb14-Mediated Cross Talk between Insulin and p62/Nrf2 Pathways Regulates Liver Lipogenesis and Selective Insulin Resistance.PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.Lack of the presynaptic RhoGAP protein oligophrenin1 leads to cognitive disabilities through dysregulation of the cAMP/PKA signalling pathway.Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments.Protein kinase A alterations in endocrine tumors.Protein kinase A alterations in adrenocortical tumors.Adrenocortical growth and cancer.Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors.Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production.AXIN genetic analysis in adrenocortical carcinomas updated.8Cl-cAMP modifies the balance between PKAR1 and PKAR2 and modulates the cell cycle, growth and apoptosis in human adrenocortical H295R cells.EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression.Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.ACTH and PRL sensitivity of highly differentiated cell lines obtained by adrenocortical targeted oncogenesis.Adrenocorticotropin/3',5'-cyclic AMP-mediated transcription of the scavenger akr1-b7 gene in adrenocortical cells is dependent on three functionally distinct steroidogenic factor-1-responsive elements.Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion.Integrated genomic characterization of adrenocortical carcinoma.A concomitant false-negative ¹⁸F-FDG PET imaging in an adrenocortical carcinoma and a high uptake in a corresponding liver metastasis.Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
P50
Q24310286-876B6489-23AB-4D73-AA4A-CC8A80D85142Q27321080-906E44E5-63FB-47F5-B419-91A83A938C91Q28247409-6526AD77-9DED-4B2D-937D-9039CAEC3236Q33509010-090E6969-4A57-4BCE-8457-35479E427E0AQ33570265-91B37898-1BBA-46C9-957B-575133D1EA51Q33604822-DE827191-5996-4B46-8172-2E2CF3348816Q33682397-AEFF311B-C1BC-4E71-983B-67BE2418F2FBQ33999643-86681B23-FA9A-4D62-8DE1-E79B19E5CECEQ34571810-88DB9265-9A0D-47C2-98A2-F271651D13D0Q34586245-B1B45AF8-A6AC-41ED-AB07-AD3AF65C9C4BQ35100928-177009BD-592C-4D6B-9CD0-6E8F90FEA1C3Q35680827-90EF7A88-A005-4160-A73D-F62B6B9F96E5Q35905777-11AB5722-A152-43FB-83A1-79E8FA23BB02Q36361438-07815B47-4B27-4FD5-840F-B53BC95C1E23Q36503899-443F6075-8B01-4E0C-9D43-1A8CE10F9B4CQ37141714-3F20102C-CFF6-4044-B94D-604966CA65E6Q37277025-8BAD1F5D-B32F-44F6-A88F-6D1E57D6AD26Q37350712-97CB0D2D-A2FB-455B-B7B1-0F92C0EB1602Q37826288-BA901BC0-2B43-4D14-B48A-2EF9AD2ED08CQ38023287-D06AAAC4-3614-41C5-B326-08D222386BDBQ38238143-841E6A6A-ECC6-4184-AEC2-AFAB7B4758F2Q38318638-7FB3DCE6-710E-49B7-B5E0-EE4419AACE74Q38536557-3604CEED-BC19-4EB8-8D73-A17C1E6AB434Q38725973-7BC72E89-884E-4CF6-AEEA-65F7F90313F8Q38803658-12FE00D2-4CD3-4DB6-B974-9275F69063A5Q39088795-8152FE6A-6415-40C0-A8EA-8E223B4BCE73Q39133079-0C4BD78C-1C21-4529-93A3-37CD9D0DDD79Q39726501-FEBCEB7D-ABB5-4125-86FA-06EA095126C5Q39791179-71107674-66A2-4072-BF6F-4095E701E1D7Q39802037-BA944930-BF3E-49A3-A1D9-63580715B6F2Q40324580-2390327E-5254-4ADC-840E-587716EDE212Q40466699-01B8AA2F-25F7-48CB-809F-572840E8E540Q40618758-D9C34D47-DBE8-4DF9-ADA7-1DE4EDF2AF09Q47801407-5371283F-9781-43F9-90A0-009E136D863FQ48153175-3485711D-A086-4448-BBD9-6A39EE0DF21DQ48315182-1AFF84A7-DA3F-4671-8D3C-726AD58D924CQ53175998-07902D37-AE54-40AA-AB54-99B6962C9DC8Q54376943-927BDCC9-68FC-4623-AB9E-95971DAA900FQ54389825-50A0699A-7AC2-45E8-8632-A387C074AED9Q54405863-52369650-257E-4AE3-9923-DFDB327EFFD6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruno Ragazzon
@ast
Bruno Ragazzon
@en
Bruno Ragazzon
@es
Bruno Ragazzon
@nl
Bruno Ragazzon
@sl
type
label
Bruno Ragazzon
@ast
Bruno Ragazzon
@en
Bruno Ragazzon
@es
Bruno Ragazzon
@nl
Bruno Ragazzon
@sl
prefLabel
Bruno Ragazzon
@ast
Bruno Ragazzon
@en
Bruno Ragazzon
@es
Bruno Ragazzon
@nl
Bruno Ragazzon
@sl
P1053
E-6541-2017
P106
P21
P2798
P31
P3829
P496
0000-0001-9476-4973